Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

Bethsabée GarelSaskia Ingen-Housz-OroDaniele AfriatCatherine Prost-SquarcioniFlorence TétartBenoit BensaidCorina Bara PassotMarie Beylot-BarryVincent DescampsSophie Duvert-LehembreSabine Grootenboer-MignotGéraldine JeudyAngele SoriaMarie Blanche Valnet-RabierAnnick BarbaudFrédéric CauxBénédicte Lebrun-Vignes

Published in: British journal of clinical pharmacology (2019)

There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.

Keyphrases

drug induced
liver injury
end stage renal disease
newly diagnosed
ejection fraction
adverse drug
peritoneal dialysis
prognostic factors
risk factors
pulmonary embolism
early onset
cross sectional
emergency department
patient reported outcomes